3 News & Press Releases found

Beta Bionics, Inc. news

Encouraging Results From a Pilot Study Testing the Bionic Pancreas in Cystic Fibrosis Related Diabetes Published in the Journal of Cystic Fibrosis.

Boston, MA-December 3,2019- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world`s first fully automated bionic pancreas today announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) delivery in three patients with cystic fibrosis related diabetes (CFRD). Results of the

Dec. 2, 2019

Beta Bionics Receives FDA Breakthrough Device Designation for the iLet Bionic Pancreas System

Boston, MA -July 1, 2019 - Beta Bionics, Inc. — a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world`s first fully automated bionic pancreas — today announced that the company has completed a S63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the total combined Series B and B2 financings to just over $126 million. Beta Bionics, In

Jun. 30, 2019

First Home-Use Trial of the iLet Bionic Pancreas System Using Pre-Filled Cartridges of Dasiglucagon Compatible With iLet Has Been Successfully Completed

Boston, MA and Copenhagen, Denmark - June 6,2019 - Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL) announced today that a home-use study of dasiglucagon in the iLet Bionic Pancreas System has been successfully completed.

Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet® bionic pancreas using dasiglucagion.

Jun. 5, 2019